Skip to main content
PCVX $59.08 +0.96%
PCVX logo
PCVX · Vaxcyte, Inc.
Track PCVX — free
$59.08 +0.56 (+0.96%) Play latest call Q4 2025 earnings call transcript
Market Cap
$9.26B
Shares
158.30M
Volume · Nov 19 188.67K Avg daily vol (3M) 2.16M
All webcasts

Earnings call · FY2026 Q3

Vaxcyte, Inc. (PCVX) Q3 2026 Earnings Call

Concluded Oct 5, 2026
Oct 5, 2026
Period
FY2026 Q3
Runtime
—
Sources
3 artifacts
Diluted EPS -$1.99
Net income -$297.06M
Open full screen 8-K 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 4, 2026
Vaxcyte reported that VAX-31 met all prespecified primary endpoints in the OPUS-1 pivotal Phase 3 trial. Third-quarter net loss was $297.1 million, while cash, cash equivalents and investments totaled $2,264.4 million as of September 30, 2026.
10-Q report · filed Nov 4, 2026
VAX-31 met all prespecified primary endpoints in the pivotal adult Phase 3 OPUS-1 trial and was well tolerated. Vaxcyte raised approximately $1.15 billion in October 2026 and held $2.3 billion of cash, cash equivalents and investments as of September 30, 2026.

The audio replay and transcript follow the call.

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document